India Pharmaceutical Export Data 2026: Growth, Trends & Forecast
Key points
Pharmaceutical exports of India are estimated to reach a record $65 Billion by the end of 2026.
While the USA remains the primary volume buyer, 2026 data show a significant "Eastward Shift" toward Southeast Asia and the CIS (Commonwealth of Independent States) region.
The API Revolution: India has successfully reduced its reliance on raw material imports, with domestic API production now supporting 35% of all Indian exports in the pharma sector.
With international audits (USFDA/EDQM) becoming more frequent, real-time data is being used as a vetting tool for manufacturing quality.
The Biosimilar Surge: For the first time, biosimilars and oncology drugs have overtaken traditional anti-infectives in export value growth.
Overview
Pharmacy of the World is not a marketing tagline anymore. It is a supply chain reality. India exported $30.4 billion worth of pharmaceuticals in FY25 — its highest ever — and the first four months of FY26 (April–July 2025) already clocked $8.15 billion. The trajectory is clear.
The export data from the Department of Commerce also reveals an important structural shift: a single HS code — 30049099 (other medicaments for retail sale) — generated nearly $9.97 billion in Apr–Feb FY26. That one sub-heading is larger than the entire pharmaceutical export basket of most countries.
Pharma exports FY25
$30.4B
+9.4% over FY24
FY26 (Apr–Jul 2025)
$8.15B
On track for record
USA share of India pharma exp.
34.61%
Largest single buyer
Countries receiving exports
200+
Including 100+ emerging markets
Export Products India — The Pharma Product Mix Driving Growth
Formulations & Biologics: Dominant Export Category
Drug formulations and biologics continue to dominate the export products India due to strong global demand for affordable medicines. Indian companies export tablets, capsules, injectables, and advanced biologic therapies to regulated and semi-regulated markets worldwide.
APIs & Drug Intermediates: Supply Chain Engine
APIs & drug intermediates forming spine of India’s pharmaceutical manufacturing ecosystem. India supplies in bulk for drug ingredients to the major pharmaceutical companies across the US, Europe, Latin America, and Asia.
Vaccines & Immunological Products
India has emerged as one of the world’s largest suppliers of vaccines and immunological products, exporting to both developed and developing nations.
HS Code Reference: India Pharmaceutical Export Data by Product Category
For exporters building a market entry plan, buyers running supplier audits, or trade analysts building intelligence models — correct HS code mapping is your starting point. Here is a reference table of India's key pharma export HS codes, with buyer market mapping and recommended data search paths on Cybex Exim.
HS 30049099 – Other medicaments for retail sale (generics) Key Markets: USA, UK, South Africa, Nigeria FY26 Value: ~$9.97B
HS 30049010 – Medicaments containing antibiotics Key Markets: USA, EU, Africa, Southeast Asia FY26 Value: High volume HS 30021500 – Immunological products / vaccines Key Markets: UNICEF, 80+ countries FY26 Value: $347.65M
HS 30039090 – Bulk drug formulations (APIs) Key Markets: USA, Europe, China FY26 Value: 16% share
HS 29420090 – Other API & drug intermediates Key Markets: USA, EU, Japan FY26 Value: Growing
HS 30059099 – Oncology & biosimilar formulations Key Markets: USA, France, Germany FY26 Value: High margin
HS 30041000 – Penicillin-based antibiotics Key Markets: Africa, CIS, Middle East FY26 Value: Mass volume
HS 30063000 – Ophthalmic preparations Key Markets: USA, UK, Brazil FY26 Value: Steady growth
India's Pharmaceutical Buyers
The USA dominates India's pharmaceutical export data with a 34.61% share but what's more interesting is the emerging market acceleration happening in parallel. Here's the full buyer picture:
USA Key Products: Generics, APIs, aero-pharma, biologics Export Value: $8.73B Market Type: Regulated
UK Key Products: Generics, formulations, OTC Export Value: $784M Market Type: Regulated
South Africa Key Products: ARVs, antibiotics, vaccines Export Value: $718M Market Type: Semi-regulated
Netherlands Key Products: Retail medicaments, generics Export Value: $699M Market Type: Regulated
France Key Products: HS 300490 formulations, specialty drugs Export Value: $667M Market Type: Regulated
Brazil Key Products: Generics, APIs, OTC brands Export Value: Growing fast Market Type: Semi-regulated
Nigeria & Africa Key Products: Antibiotics, vaccines, essential drugs Export Value: High volume Market Type: Emerging
Russia & CIS Key Products: Branded generics, APIs Export Value: Expanding Market Type: Emerging
What’s Reshaping India's Pharmaceutical Exports in 2026
Negotiations among India-EU Free Trade Agreement
For exporters, which directly reduces non-tariff barriers, accelerates regulatory cooperation on drug approvals, and opens procurement channels across France, Netherlands, Germany, Belgium, and Malta.
Chronic Disease & Therapies
Retail medicament exports are growing, but the value-per-unit story sits in oncology, cardiovascular, anti-diabetic, and respiratory categories. Countries across North America, Europe, and Latin America are sourcing affordable chronic disease medication from India as domestic healthcare costs rise.
China Plus One API Sourcing Is Flowing Directly to India
Rising geopolitical pressure on China-dependent API supply chains has accelerated pharma buyers' diversification toward India. The PLI scheme's investment in 41 critical API ingredients with ₹6,940 crore outlay through 2029–30 is converting this demand into real production capacity.
Forecasting of India's Pharma Export Story Headed by 2030
Estimated Market insights 2026–2030
India pharmaceutical market revenue $43B (2025) to $80B (2033)
CAGR of 8.1% through the forecast period (Grand View Research)
Targeted Pharma Export : $50 billion+ by 2030
Driven by India–EU FTA, US generics demand, biosimilar expansion, and PLI-backed API capacity
CRDMO industry expected to double to $14 billion by 2028
India is transitioning from generics exporter to full pharmaceutical value chain partner — CRDMOs, GCCs, and innovation-led biologics are the next growth lever
Frequently Asked Questions
1.Which countries are the top buyers of Indian pharmaceutical exports?
The USA leads with a 34.61% share, followed by the UK (3.01%), South Africa (2.40%), Netherlands, France, Brazil, Nigeria, and Russia.
2.What are the top export products from India in the pharmaceutical sector?
Formulations and biologics (79.26% share), drug intermediates and APIs (16.08%), vaccines and immunological products, and specialty drugs including oncology and biosimilar formulations.
3. What certifications do Indian pharma exporters need for US and EU markets?
USFDA approval for the manufacturing plant (for US market), EU GMP certification (for European buyers), WHO-GMP certification (for emerging market tenders), and Schedule M compliance under Indian drug law.
4. What is the "Biosimilar" opportunity?
Biosimilars are highly complex versions of biological drugs as they are harder to make than traditional generics, they offer much higher profit margins.
5. Why is real-time trade data better than annual reports?
Annual reports tell you where the market was. Real-time Export Data tells you where the market is going, allowing you to pivot your production before the competition does.













